Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
Hutch is the only National Cancer Institute-designated cancer center in Washington. With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19
-
for faculty positions in both of hematological malignancies as well as in solid tumors with a focus on Immunotherapies. These positions will be homed in the Department of Medicine, with strong collaboration
-
Certification from American Heart Association (AHA) required Work Experience 1 year acute care experience in a specialty required 1 year For Infusion Center: ONS Chemo/Immunotherapy Certified required 2 years
-
. Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol5, 526 (2014). https
-
Specialist C/D Job Profile Title Research Specialist C Job Description Summary The Research Specialist C/D position in The Center for Cellular Immunotherapies will support research efforts in CAR T-cell
-
duties · Acute and chronic outpatient care of Neuro-Oncology patients including administration of chemotherapy and immunotherapy, disease-modifying therapy, and health maintenance care
-
biomarker discovery and immunotherapy strategies, while providing unparalleled training in spatial biology, immunology, and translational cancer research. Principal Supervisor: Dr Judith Ramage (Judith.ramage
-
carrying RNA payloads). * Familiarity with preclinical models for immunotherapy or targeted RNA delivery. * Previous experience leading projects with CRO and translational research initiatives. * Strong
-
Hutch is the only National Cancer Institute-designated cancer center in Washington. With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19
-
Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S) | Portugal | 2 months ago
responses to pathogens and vaccines or the development of autoimmunity. Consequently, the design of new immunotherapies for haematological diseases associated with dysfunctional T cell responses also relies